Academic Appointments

Administrative Appointments

  • Director, Phase I Clinical Research Program, Division of Oncology, Stanford School of Medicine (2015 - Present)
  • Professor of Medicine, Department of Medicine (2015 - Present)
  • co-Director, Translational Oncology Program at Stanford, Stanford Cancer Institute (2016 - Present)
  • Associate Division Chief for Faculty Affairs, Division of Medical Oncology, Department of Medicine (2019 - Present)
  • Medical Director, Clinical and Translational Unit, Stanford School of Medicine (2019 - Present)

Research & Scholarship

Current Research and Scholarly Interests

Dr. Kummar?s research interests focus on developing novel therapies for cancer. She specializes in conducting pharmacokinetic and pharmacodynamic driven first-in-human trials tailored to make early, informed decisions regarding the suitability of novel molecular agents for further clinical investigation. Her studies integrate genomics and laboratory correlates into early phase trials. She is interested in alternate trial designs to facilitate rational drug selection based on human data and help expedite drug development timelines. She has published numerous articles in medical journals and serves on a number of national and international scientific committees.

Clinical Trials

  • A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion Recruiting

    This is a Phase I/II, open-label, multi-center, multi-national, dose escalation, single agent study to assess the safety, tolerability, PK, PD, immunogenicity and anti-tumor activity of zenocutuzumab (MCLA-128) in patients with solid tumors harboring an NRG1 fusion.

    View full details

  • A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer Recruiting

    This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study also investigates how the drug is absorbed and processed in the human body, and how well and for how long the cancer responds to the drug. This is the first study to test selitrectinib in humans with cancer, for whom no other effective therapy exists.

    View full details

  • Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Recruiting

    This study evaluates nirogacestat in the treatment of desmoid tumor/aggressive fibromatosis (DT/AF). Half of the participants will receive nirogacestat while the other half will receive placebo.

    View full details

  • Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) Recruiting

    This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS). All participants with ASPS will receive open-label AL3818. In participants with LMS or SS, AL3818 will be compared to IV dacarbazine. Two-thirds of the participants will receive AL3818, one-third of the participants will receive IV dacarbazine.

    View full details

  • Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting

    This study evaluates ADCT-301 in patients with Selected Advanced Solid Tumors. Patients will participate in a Treatment Period with 3-week cycles and a Follow-up Period every 12 weeks for up to 1 year after treatment discontinuation.

    View full details

  • Study of ORIC-101 in Combination With Anticancer Therapy Recruiting

    The purpose of this study is to establish the recommended Phase 2 dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of ORIC-101 in combination with nab-paclitaxel or other anticancer therapies when administered to patients with advanced or metastatic solid tumors.

    View full details

  • Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer Recruiting

    This is an open-label, exploratory study to evaluate nivolumab with or without ipilimumab based on percentage of tumoral CD8 cells at the time of treatment in participants with varying advanced solid tumors. Participants who have a tumor with ? 15% CD8 cells (classified as CD8 high) will receive nivolumab monotherapy, and participants who have a tumor with < 15% CD8 cells (classified as CD8 low) will receive ipilimumab in combination with nivolumab.

    View full details

  • A Phase 2 Study of ABI-009 in Patients With Advanced Malignant PEComa Not Recruiting

    A phase 2 multi-center investigation of efficacy of ABI-009 (nab-sirolimus) in patients with advanced malignant perivascular epithelioid cell tumor (PEComa). Funding Source - FDA OOPD

    Stanford is currently not accepting patients for this trial. For more information, please contact Maria Ahern, 650-725-6413.

    View full details

  • A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Not Recruiting

    To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors Not Recruiting

    The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX8394.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities Not Recruiting

    This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard therapy or for which no standard therapy exists, particularly urothelial cancer, biliary tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors Not Recruiting

    This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Not Recruiting

    This is a phase 1b/2, open-label, multicenter trial designed to evaluate the safety, tolerability, biologic activity, and preliminary efficacy of intratumoral SD-101 injections in combination with intravenous pembrolizumab in patients with metastatic melanoma or recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). This study will be conducted in 2 phases. Phase 1 evaluates SD-101 given in combination with pembrolizumab in melanoma populations (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with progressive disease) in up to 4 Dose Escalation cohorts to identify a recommended Phase 2 dose (RP2D) to be evaluated in up to 4 Dose Expansion cohorts in Phase 2. Phase 2 also includes up to 4 Dose Expansion cohorts of patients with HNSCC (anti-PD-1/L1 naïve and anti-PD-1/L1 experienced with progressive disease).

    Stanford is currently not accepting patients for this trial. For more information, please contact Kristine McGlennen, 650-723-3589.

    View full details

  • An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma Not Recruiting

    The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

    Stanford is currently not accepting patients for this trial. For more information, please contact Kristine McGlennen, 650-723-3589.

    View full details

  • JTX-2011 Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors Not Recruiting

    JTX-2011-101 is a Phase 1/2, open label, dose escalation and expansion clinical study of JTX-2011 alone and in combination with nivolumab, ipilimumab, or pembrolizumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Not Recruiting

    This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery (unresectable). M6620 and irinotecan hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

    Stanford is currently not accepting patients for this trial. For more information, please contact Shivaani Kummar, 800-411-1222.

    View full details

  • Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer Not Recruiting

    This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

    Stanford is currently not accepting patients for this trial. For more information, please contact Site Public Contact, 650-498-7061.

    View full details

  • Phase 1/1b Study to Evaluate the Safety and Tolerability of Ciforadenant Alone and in Combination With Atezolizumab in Advanced Cancers Not Recruiting

    This is a phase 1/1b open-label, multicenter, dose-selection study of ciforadenant, an oral small molecule targeting the adenosine-A2A receptor on T-lymphocytes and other cells of the immune system. This trial will study the safety, tolerability, and anti-tumor activity of ciforadenant as a single agent and in combination with atezolizumab, a PD-L1 inhibitor against various solid tumors. Ciforadenant blocks adenosine from binding to the A2A receptor. Adenosine suppresses the anti-tumor activity of T cells and other immune cells.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • Safety Study of MGD009 in B7-H3-expressing Tumors Not Recruiting

    The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • SD-101 and BMS-986178 in Treating Patients With Advanced or Metastatic Solid Malignancies Not Recruiting

    This phase I trial studies the side effects of intratumoral injection of SD-101 and BMS-986178 in treating patients with solid malignancies that have spread to other places in the body. The TLR9 agonist SD-101 may stimulate the immune system in different ways and stop cancer cells from growing. BMS-986178 is a monoclonal anti-OX40 antibody that enhances the activation of T cells, immune cells that are important for fighting tumors. Giving TLR9 agonist SD-101 together with anti-OX40 antibody BMS-986178 may work better in treating patients with advanced solid tumors.

    Stanford is currently not accepting patients for this trial. For more information, please contact Jee Min Lee, 650-497-5240.

    View full details

  • Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression Not Recruiting

    This study evaluated ADCT-502 in participants with Advanced Solid Tumors with HER2 Expression. Participants participated in a dose-escalation phase (Part 1) and were due to participate in the dose expansion phase (Part 2). In Part 2, patients were due to receive the dose level identified in Part 1, but the study was terminated prior to the beginning of Part 2.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details

  • Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor Not Recruiting

    This is a phase 1/2 single arm, open-label, safety, tolerability, and PK study of Cabiralizumab in PVNS/dt-TGCT patients. Patients will be enrolled into either Phase 1 (dose escalation) or Phase 2 (dose expansion) of the study, but not both.

    Stanford is currently not accepting patients for this trial. For more information, please contact Maria Ahern, 650-725-6413.

    View full details

  • Study of the Safety, Pharmacokinetics and Efficacy of EDO-S101, in Patients With Advanced Solid Tumors Not Recruiting

    Tinostamustine (EDO-S101) is a new chemical entity, an AK-DAC (a first-in-class alkylating deacetylase inhibiting molecule), that in pre-clinical studies has been shown to simultaneously improve access to the DNA strands within cancer cells, break them and block damage repair. This Phase 1/2 study will enroll patients with various advanced solid tumors.

    Stanford is currently not accepting patients for this trial. For more information, please contact Shivaani Kummar, MD, 650-724-9084.

    View full details

  • Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) Not Recruiting

    This is an open-label Phase 2 randomized study that will examine the use of the study agents, CMB305 (sequentially administered LV305 which is a dendritic cell-targeting viral vector expressing the New York Esophageal Squamous Cell Carcinoma 1 gene [NY-ESO-1] and G305 which is a NY-ESO-1 recombinant protein plus glucopyranosyl lipid adjuvant-stable emulsion [GLA-SE]) in combination with atezolizumab or atezolizumab alone, in participants with locally advanced, relapsed or metastatic sarcoma (synovial or myxoid/round cell liposarcoma) expressing the NY-ESO-1 protein. There is no formal primary hypothesis for this study.

    Stanford is currently not accepting patients for this trial. For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.

    View full details


2020-21 Courses


All Publications

  • Durability of Response with Larotrectinib in Adult and Pediatric Patients with TRK Fusion Cancer Leyvraz, S., Hyman, D. M., van Tilburg, C. M., Albert, C. M., Tan, D., Geoerger, B., Farago, A. F., Laetsch, T. W., Kummar, S., Doz, F., Lassen, U., Dubois, S. G., Mcdermott, R., Mascarenhas, L., Berlin, J., Rudzinski, E. R., Cox, M. C., Nanda, S., Childs, B. H., Drilon, A., Hong, D. S. KARGER. 2020: 204
  • Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. The Lancet. Oncology Hong, D. S., DuBois, S. G., Kummar, S., Farago, A. F., Albert, C. M., Rohrberg, K. S., van Tilburg, C. M., Nagasubramanian, R., Berlin, J. D., Federman, N., Mascarenhas, L., Geoerger, B., Dowlati, A., Pappo, A. S., Bielack, S., Doz, F., McDermott, R., Patel, J. D., Schilder, R. J., Tahara, M., Pfister, S. M., Witt, O., Ladanyi, M., Rudzinski, E. R., Nanda, S., Childs, B. H., Laetsch, T. W., Hyman, D. M., Drilon, A. 2020


    The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.Patients were enrolled and treated in a phase 1 adult, a phase 1/2 paediatric, or a phase 2 adolescent and adult trial. Some eligibility criteria differed between these studies. For this pooled analysis, eligible patients were aged 1 month or older, with a locally advanced or metastatic non-CNS primary, TRK fusion-positive solid tumour, who had received standard therapy previously if available. This analysis set includes the 55 patients on which approval of larotrectinib was based. Larotrectinib was administered orally (capsule or liquid formulation), on a continuous 28-day schedule, to adults mostly at a dose of 100 mg twice daily, and to paediatric patients mostly at a dose of 100 mg/m2 (maximum of 100 mg) twice daily. The primary endpoint was objective response as assessed by local investigators in an intention-to-treat analysis. Contributing trials are registered with, NCT02122913 (active not recruiting), NCT02637687 (recruiting), and NCT02576431 (recruiting).Between May 1, 2014, and Feb 19, 2019, 159 patients with TRK fusion-positive cancer were enrolled and treated with larotrectinib. Ages ranged from less than 1 month to 84 years. The proportion of patients with an objective response according to investigator assessment was 121 (79%, 95% CI 72-85) of 153 evaluable patients, with 24 (16%) having complete responses. In a safety population of 260 patients treated regardless of TRK fusion status, the most common grade 3 or 4 larotrectinib-related adverse events were increased alanine aminotransferase (eight [3%] of 260 patients), anaemia (six, 2%), and decreased neutrophil count (five [2%]). The most common larotrectinib-related serious adverse events were increased alanine aminotransferase (two [<1%] of 260 patients), increased aspartate aminotransferase (two [<1%]), and nausea (two [<1%]). No treatment-related deaths occurred.These data confirm that TRK fusions define a unique molecular subgroup of advanced solid tumours for which larotrectinib is highly active. Safety data indicate that long-term administration of larotrectinib is feasible.Bayer and Loxo Oncology.

    View details for DOI 10.1016/S1470-2045(19)30856-3

    View details for PubMedID 32105622

  • Phase I trial of the combination of bortezomib and clofarabine in adults with refractory solid tumors, lymphomas, or myelodysplastic syndromes Khan, S. S., O'Sullivan, G., Rubinstein, L., Kummar, S., Juwara, L., Zlott, J., Mittra, A., Hogu, M., Collins, J., Srivastava, A., Miller, B., Parchment, R. E., Hourigan, C. S., Pavletic, S., Doroshow, J., Chen, A. P., Takebe, N. AMER ASSOC CANCER RESEARCH. 2019
  • Validation of beta-catenin as a tumor segmentation marker for delineating tumor from stromal tissues in quantitative multiplex immunofluorescence analysis of formalin-fixed, paraffin-embedded biopsy specimens Navas, T., Kinders, R. J., Makhlouf, H., Lawrence, S. M., Chuaqui, R., Fino, K., Dull, A., Ferry-Galow, K., Wilsker, D., Chen, A. P., Kummar, S., Parchment, R. E., Doroshow, J. H. AMER ASSOC CANCER RESEARCH. 2019
  • Tolerability and antitumor activity of paclitaxel is improved by the addition of nilotinib in patients with refractory solid tumors Coyne, G., Kummar, S., Zlott, J., Juwara, L., Takebe, N., Hogu, M., Anderson, L., Collins, J., Piekarz, R., Streicher, H., Sharon, E., Mittra, A., Khan, S., Miller, B., Navas, T., Srivastava, A., Parchment, R., Rubinstein, L., Doroshow, J. H., Chen, A. P. AMER ASSOC CANCER RESEARCH. 2019
  • Cediranib phase-II study in children with metastatic alveolar soft-part sarcoma (ASPS). Pediatric blood & cancer Cohen, J. W., Widemann, B. C., Derdak, J., Dombi, E., Goodwin, A., Dompierre, J., Onukwubiri, U., Steinberg, S. M., O'Sullivan Coyne, G., Kummar, S., Chen, A. P., Glod, J. 2019: e27987


    BACKGROUND: Alveolar soft-part sarcoma (ASPS), a rare vascular sarcoma with a clinically indolent course, frequently presents with metastases. Vascular endothelial growth factor (VEGF) is a promising therapeutic target. In a phase-II trial of the VEGF receptor inhibitor cediranib for adults with ASPS, the partial response (PR) rate (response evaluation criteria in solid tumors [RECIST] v1.0) was 35% (15/43; 95% confidence interval: 21-51%). We evaluated cediranib in the pediatric population.PROCEDURE: Patients <16 years old with metastatic, unresectable ASPS received cediranib at the pediatric maximum tolerated dose of 12 mg/m2 (70% of the fixed adult phase-II dose orally daily). Tumor response was assessed every two cycles (RECIST v1.0). A Simon two-stage optimal design (target response rate 35%, rule out 5%) was used.RESULTS: Seven patients (four females), with a median age of 13 years, (range 9-15), were enrolled on stage 1. The most frequent grade 2 or 3 adverse events were neutropenia, diarrhea, hypertension, fatigue, and proteinuria. The best response was stable disease (SD) (median cycle number = 34). Three patients were removed from the study treatment for disease progression (cycles 4, 5, and 36). Five of seven patients had SD for ?14 months. Two patients with SD remain on study (34-57+ cycles).CONCLUSIONS: Cediranib did not reach the target response rate in this small pediatric cohort, in contrast to the adult 35% PR rate. The pediatric dosing was 30% lower compared to the adult dosing, which may have contributed to response differences. Prolonged SD was observed in five patients, but given the indolent nature of ASPS, SD cannot be clearly attributed to cediranib. Cediranib has an acceptable safety profile.

    View details for DOI 10.1002/pbc.27987

    View details for PubMedID 31502400

  • NCI-MATCH EAY131-Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations Kummar, S., Li, S., Reiss, K., Ford, J. M., Mitchell, E. P., Zwiebel, J. A., Takebe, N., Gray, R. J., McShane, L. M., Rubinstein, L. V., Patton, D., Williams, P., Hamilton, S. R., Brufsky, A., Conley, B. A., Arteaga, C. L., Harris, L. N., O'Dwyer, P. J., Chen, A. P., Flaherty, K. T. AMER ASSOC CANCER RESEARCH. 2019
  • Dose escalation of tinostamustine in patients with advanced solid tumors Mita, A., Loeffler, M., Bui, N., Mehrling, T., Rimmel, B. J., Natale, R. B., Kummar, S. AMER ASSOC CANCER RESEARCH. 2019
  • Improved progression-free and overall survival (PFS/OS) in patients (pts) with emergence of JTX-2011 associated biomarker (ICOS high CD4 T cells) on the ICONIC trial Yap, T., Gainor, J. F., Callahan, M. K., Falchook, G. S., Pachynski, R., LoRusso, P., Kummar, S., Gibney, G., Burris, H. A., Tykodi, S. S., Rahma, O. E., Seiwert, T., Papadopoulos, K. P., Hooper, E., Harvey, C. J., Hanson, A., Lacey, S., McComb, R., Hart, C., Laken, H., McClure, T., Trehu, E. AMER ASSOC CANCER RESEARCH. 2019
  • Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) Hyman, D., Kummar, S., Farago, A., Geoerger, B., Mau-Sorensen, M., Taylor, M., Garralda, E., Nagasubramanian, R., Natheson, M., Song, L., Capra, M., Jorgensen, M., Ho, A., Shukla, N., Smith, S., Huang, X., Tuch, B., Ku, N., Laetsch, T. W., Drilon, A., Hong, D. AMER ASSOC CANCER RESEARCH. 2019
  • Larotrectinib efficacy and safety in adult TRK fusion cancer patients. Hong, D. S., Kummar, S., Farago, A. F., Lassen, U., Berlin, J., Schilder, R. J., McDermott, R. S., Patel, J. D., Dowlati, A., Doebele, R., Tan, D., Lee, J. J., Nanda, S., Childs, B. H., Ku, N., Drilon, A. E., Hyman, D. AMER SOC CLINICAL ONCOLOGY. 2019
  • Safety and tolerability of veliparib, an oral PARP inhibitor, and M6620 (VX-970), an ATR inhibitor, in combination with cisplatin in patients with refractory solid tumors. Mittra, A., Coyne, G., Do, K., Piha-Paul, S., Kummar, S., Takebe, N., Bruns, A., Juwara, L., Rubinstein, L., Hogu, M., Kinders, R. J., Parchment, R. E., Miller, B., Wilsker, D., Monge, M. B., Khan, S., Doyle, L., Doroshow, J. H., Chen, A. P. AMER SOC CLINICAL ONCOLOGY. 2019
  • Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib. Kummar, S., Mascarenhas, L., Geoerger, B., Turpin, B., Cox, M., Yu, S., Nanda, S., Hiemeyer, F., Keating, K. N., Chirila, C., Gnanasakthy, A., Davenport, E., Hong, D. S., Drilon, A. E. AMER SOC CLINICAL ONCOLOGY. 2019
  • Biodistribution, Tumor Detection, and Radiation Dosimetry of F-18-5-Fluoro-2 '-Deoxycytidine with Tetrahydrouridine in Solid Tumors JOURNAL OF NUCLEAR MEDICINE Young, C. R., Adler, S., Eary, J. F., Lindenberg, M., Jacobs, P. M., Collins, J., Kummar, S., Kurdziel, K. A., Choyke, P. L., Mena, E. 2019; 60 (4): 492?96
  • Evaluation of pharmacodynamic responses to cancer therapeutic agents using DNA damage markers. Clinical cancer research : an official journal of the American Association for Cancer Research Wilsker, D. F., Barrett, A. M., Dull, A. B., Lawrence, S. M., Hollingshead, M. G., Chen, A., Kummar, S., Parchment, R. E., Doroshow, J. H., Kinders, R. J. 2019


    PURPOSE: We sought to examine the pharmacodynamic activation of the DNA damage response (DDR) pathway in tumors following anticancer treatment for confirmation of target engagement.EXPERIMENTAL DESIGN: We evaluated the time course and spatial activation of 3 protein biomarkers of DNA damage recognition and repair (gammaH2AX, pS343-Nbs1, and Rad51) simultaneously in a quantitative multiplex immunofluorescence assay (IFA) to assess DDR pathway activation in tumor tissues following exposure to DNA-damaging agents.RESULTS: Due to inherent biological variability, baseline DDR biomarker levels were evaluated in a colorectal cancer microarray to establish clinically-relevant thresholds for pharmacodynamic activation. Xenograft-bearing mice and clinical colorectal tumor biopsies obtained from subjects exposed to DNA damaging therapeutic regimens demonstrated marked intra-tumor heterogeneity in the timing and extent of DDR biomarker activation, due in part to the cell-cycle dependency of DNA damage biomarker expression.CONCLUSIONS: We have demonstrated the clinical utility of this DDR multiplex IFA in preclinical models and clinical specimens following exposure to multiple classes of cytotoxic agents, DNA repair protein inhibitors, and molecularly-targeted agents, in both homologous recombination-proficient and -deficient contexts. Levels exceeding 4% nuclear area positive (NAP) gammaH2AX, 4% NAP pS343-Nbs1, and 5% cells with ?5 Rad51 nuclear foci indicate a DDR activation response to treatment in human colorectal cancer tissue. Determination of effect-level cutoffs allows for robust interpretation of biomarkers with significant inter-patient and intra-tumor heterogeneity; simultaneous assessment of biomarkers induced at different phases of the DNA damage response guards against the risk of false negatives due to an ill-timed biopsy.

    View details for DOI 10.1158/1078-0432.CCR-18-2523

    View details for PubMedID 30792217

  • Adenosine A2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer. Cancer discovery Fong, L., Hotson, A., Powderly, J., Sznol, M., Heist, R. S., Choueiri, T. K., George, S., Hughes, B. G., Hellmann, M. D., Shepard, D. R., Rini, B. I., Kummar, S., Weise, A. M., Riese, M. J., Markman, B., Emens, L. A., Mahadevan, D., Luke, J. J., Laport, G., Brody, J. D., Hernandez-Aya, L., Bonomi, P., Goldman, J. W., Berim, L., Renouf, D. J., Goodwin, R. A., Munneke, B., Ho, P. Y., Hsieh, J., McCaffery, I., Kwei, L., Willingham, S. B., Miller, R. A. 2019


    Adenosine mediates immunosuppression within the tumor microenvironment through triggering adenosine 2A receptors (A2AR) on immune cells. To determine whether this pathway could be targeted as an immunotherapy, we performed a phase 1 clinical trial with a small molecule A2AR antagonist. We find that this molecule can safely block adenosine signaling in vivo. In a cohort of 68 renal cell cancer (RCC) patients, we also observe clinical responses alone and in combination with an anti-PD-L1 antibody, including subjects who had progressed on PD-(L)1 inhibitors. Durable clinical benefit is associated with increased recruitment of CD8+ T cells into the tumor. Treament can also broaden the circulating T cell repertoire. Clinical responses are associated with an adenosine-regulated gene expression signature in pre-treatment tumor biopsies. A2AR signaling, therefore, represents a targetable immune checkpoint distinct from PD-(L)1 that restricts anti-tumor immunity.

    View details for DOI 10.1158/2159-8290.CD-19-0980

    View details for PubMedID 31732494

  • Clinical Evolution of Epithelial-Mesenchymal Transition in Human Carcinomas. Cancer research Navas, T., Kinders, R. J., Lawrence, S. M., Ferry-Galow, K. V., Borgel, S., Hollingshead, M. G., Srivastava, A. K., Alcoser, S. Y., Makhlouf, H. R., Chuaqui, R., Wilsker, D. F., Konaté, M. M., Miller, S. B., Voth, A. R., Chen, L., Vilimas, T., Subramanian, J., Rubinstein, L., Kummar, S., Chen, A. P., Bottaro, D. P., Doroshow, J. H., Parchment, R. E. 2019


    The significance of the phenotypic plasticity afforded by epithelial-mesenchymal transition (EMT) for cancer progression and drug resistance remains to be fully elucidated in the clinic. We evaluated epithelial-mesenchymal phenotypic characteristics across a range of tumor histologies using a validated, high resolution digital microscopic immunofluorescence assay (IFA) that incorporates ?-catenin detection and cellular morphology to delineate carcinoma cells from stromal fibroblasts and that quantitates the individual and co-localized expression of the epithelial marker E-cadherin (E) and the mesenchymal marker vimentin (V) at subcellular resolution ("EMT IFA"). We report the discovery of ?-catenin+ cancer cells that co-express E-cadherin and vimentin in core needle biopsies from patients with various advanced metastatic carcinomas wherein these cells are transitioning between strongly epithelial and strongly mesenchymal-like phenotypes. Treatment of carcinoma models with anticancer drugs that differ in their mechanism of action (the tyrosine kinase inhibitor pazopanib in MKN45 gastric carcinoma xenografts, and the combination of tubulin-targeting agent paclitaxel with the BCR-ABL inhibitor nilotinib in MDA-MB-468 breast cancer xenografts) caused changes in the tumor epithelial-mesenchymal character. Moreover, the appearance of partial-EMT or mesenchymal-like carcinoma cells in MDA-MB-468 tumors treated with the paclitaxel-nilotinib combination resulted in upregulation of cancer stem cell (CSC) markers and susceptibility to FAK inhibitor. A metastatic prostate cancer patient treated with the PARP inhibitor talazoparib exhibited similar CSC marker upregulation. Therefore, the phenotypic plasticity conferred on carcinoma cells by EMT allows for rapid adaptation to cytotoxic or molecularly-targeted therapy and could create a form of acquired drug resistance that is transient in nature.

    View details for DOI 10.1158/0008-5472.CAN-18-3539

    View details for PubMedID 31732654

  • Reviewing the role of healthy volunteer studies in drug development. Journal of translational medicine Karakunnel, J. J., Bui, N., Palaniappan, L., Schmidt, K. T., Mahaffey, K. W., Morrison, B., Figg, W. D., Kummar, S. 2018; 16 (1): 336


    BACKGROUND: With the exception of genotoxic oncology drugs, first-in-human, Phase 1 clinical studies of investigational drugs have traditionally been conducted in healthy volunteers (HVs). The primary goal of these studies is to investigate the pharmacokinetics and pharmacodynamics of a novel drug candidate, determine appropriate dosing, and document safety and tolerability.MAIN BODY: When tailored to specific study objectives, HV studies are beneficial to manufacturers and patients alike and can be applied to both non-oncology and oncology drug development. Enrollment of HVs not only increases study accrual rates for dose-escalation studies but also alleviates the ethical concern of enrolling patients with disease in a short-term study at subtherapeutic doses when other studies (e.g. Phase 2 or Phase 3 studies) may be more appropriate for the patient. The use of HVs in non-oncology Phase 1 clinical trials is relatively safe but nonetheless poses ethical challenges because of the potential risks to which HVs are exposed. In general, most adverse events associated with non-oncology drugs are mild in severity, and serious adverse events are rare, but examples of severe toxicity have been reported. The use of HVs in the clinical development of oncology drugs is more limited but is nonetheless useful for evaluating clinical pharmacology and establishing an appropriate starting dose for studies in cancer patients. During the development of oncology drugs, clinical pharmacology studies in HVs have been used to assess pharmacokinetics, drug metabolism, food effects, potential drug-drug interactions, effects of hepatic and renal impairment, and other pharmacologic parameters vital for clinical decision-making in oncology. Studies in HVs are also being used to evaluate biosimilars versus established anticancer biologic agents.CONCLUSION: A thorough assessment of toxicity and pharmacology throughout the drug development process is critical to ensure the safety of HVs. With the appropriate safeguards, HVs will continue to play an important role in future drug development.

    View details for PubMedID 30509294

  • Biodistribution, tumor detection and radiation dosimetry of F-18 5-Fluoro-2'-Deoxycytidine (18F-FdCyd) with Tetrahydrouridine in solid tumors. Journal of nuclear medicine : official publication, Society of Nuclear Medicine Young, C. R., Adler, S., Eary, J. F., Lindenberg, M. L., Jacobs, P. M., Collins, J., Kummar, S., Kurdziel, K. A., Choyke, P. L., Mena, E. 2018


    In pre-clinical studies, 5-fluoro-2'-deoxycytidine (FdCyd), an inhibitor of DNA methyltransferase and DNA hypermethylation, has shown treatment efficacy against multiple malignancies by suppressing epigenetic hypermethylation in tumor cells. Several clinical trials are undergoing using FdCyd and while some patients may respond to this drug, in the majority of patients it is ineffective. Thus, by establishing a non-invasive imaging modality to evaluate the distribution of the drug may provide insight into the variable responses. Objective: A novel experimental radiopharmaceutical, Fluorine-18 labeled FdCyd (18F-FdCyd), was developed as a companion imaging agent to the non-radioactive form of the drug, FdCyd. We present the first-in human radiation dosimetry results and biodistribution of 18F-FdCyd, administered along with tetrahydrouridine, an inhibitor of cytidine/deoxycytidine deaminase, in patients with a variety of solid tumors undergoing FdCyd therapy. Methods: This phase 0 imaging trial examined the 18F-FdCyd biodistribution and radiation dosimetry in 5 human subjects enrolled in companion therapy trials. In each subject, four sequential PET scans were acquired to estimate whole body and individual organ effective dose, using OLINDA/EXM v1.0. Tumor to background (T:B) ratios were also calculated for the tumor sites visualized on PET/CT imaging. Results: Average whole body effective dose for the experimental radiopharmaceutical 18F-FdCyd administered in conjunction with tetrahydrouridine was 2.12E-02 ± 4.15E-03 mSv/MBq. This is similar to the radiation dose estimates for 18F-FDG PET. The critical organ, with the highest absorbed radiation dose was the urinary bladder wall at 7.96E-02 mSv/MBq. Other organ doses of note were the liver (6.02E-02mSv/MBq), kidneys (5.26E-02 mSv/MBq), and gallbladder (4.05E-02 mSv/MBq). Tumor target to background ratios ranged from 2.4 to 1.4, which potentially enable tumor visualization in static PET images. Conclusion: This phase 0 imaging clinical trial provides evidence that 18F-FdCyd administered in conjunction with tetrahydrouridine yields acceptable individual organ and whole body effective doses, as well as modest T:B ratios that potentially enable tumor visualization. Dose estimates for 18F-FdCyd are comparable to those of other PET radiopharmaceuticals such as 18F-FDG. Further studies with larger study population are warranted to assess 18F-FdCyd imaging as a predictor of FdCyd treatment effectiveness.

    View details for PubMedID 30389817

  • TRK Inhibition: A New Tumor-Agnostic Treatment Strategy. Targeted oncology Kummar, S., Lassen, U. N. 2018


    Oncogenic somatic chromosomal rearrangements involving the NTRK1, NTRK2 or NTRK3 genes (NTRK gene fusions) occur in up to 1% of all solid tumors, and have been reported across a wide range of tumor types. The fusion proteins encoded by such rearranged sequences have constitutively activated TRK tyrosine kinase domains, providing novel therapeutic anticancer targets. The potential clinical effectiveness of TRK inhibition in patients with tumors harboring NTRK gene fusions is being assessed in phase I and II trials of TRK inhibitors, such as larotrectinib and entrectinib. Clinical trial results have demonstrated that larotrectinib is generally well tolerated and has shown high response rates that are durable across tumor types. These data validate NTRK gene fusions as actionable genomic alterations. In this review, we present the clinical data, discuss the different approaches that might be used to routinely screen tumors to indicate the presence of NTRK gene fusions, explore the issue of acquired resistance to TRK inhibition, and reflect on the wider regulatory considerations for tumor site agnostic TRK inhibitor drug development.

    View details for PubMedID 30276762

  • SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study CANCER DISCOVERY Ribas, A., Medina, T., Kummar, S., Amin, A., Kalbasi, A., Drabick, J. J., Barve, M., Daniels, G. A., Wong, D. J., Schmidt, E., Candia, A. F., Coffmanm, R. L., Leung, A. F., Janssen, R. S. 2018; 8 (10): 1250?57


    PD-1 inhibitors are approved for treating advanced melanoma, but resistance has been observed. This phase Ib trial evaluated intratumoral SD-101, a synthetic CpG oligonucleotide that stimulates Toll-like receptor 9 (TLR9), in combination with pembrolizumab in patients with unresectable or metastatic malignant melanoma. The most common adverse events related to SD-101 were injection-site reactions and transient, mild-to-moderate "flu-like" symptoms. Among the 9 patients naïve to anti-PD-1 therapy, the overall response rate (ORR) was 78%. The estimated 12-month progression-free survival rate was 88%, and the overall survival rate was 89%. Among 13 patients having prior anti-PD-1 therapy, the ORR was 15%. RNA profiling of tumor biopsies demonstrated increased CD8+ T cells, natural killer cells, cytotoxic cells, dendritic cells, and B cells. The combination of intratumoral SD-101 and pembrolizumab was well tolerated and induced broad immune activation in the tumor microenvironment with durable tumor responses in both peripheral and visceral lesions.Significance: These early data demonstrate that the combination of pembrolizumab with intratumoral SD-101 is well tolerated and can induce immune activation at the tumor site. Combining an intratumoral TLR9 innate immune stimulant with PD-1 blockade can potentially increase clinical efficacy with minimal additional toxicity relative to PD-1 blockade alone. Cancer Discov; 8(10); 1250-7. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 1195.

    View details for PubMedID 30154193

  • Clinicopathologic Features of Non-Small-Cell Lung Cancer Harboring an NTRK Gene Fusion JCO PRECISION ONCOLOGY Farago, A. F., Taylor, M. S., Doebele, R. C., Zhu, V. W., Kummar, S., Spira, A., Boyle, T. A., Haura, E. B., Arcila, M. E., Benayed, R., Aisner, D. L., Horick, N. K., Lennerz, J. K., Le, L. P., Iafrate, A., Ou, S., Shaw, A. T., Mino-Kenudson, M., Drilon, A. 2018; 2


    Gene rearrangements involving NTRK1/2/3 can generate fusion oncoproteins containing the kinase domains of TRKA/B/C, respectively. These fusions are rare in non-small cell lung cancer (NSCLC), with frequency previously estimated to be <1%. Inhibition of TRK signaling has led to dramatic responses across tumor types with NTRK fusions. Despite the potential benefit of identifying these fusions, the clinicopathologic features of NTRK fusion-positive NSCLCs are not well characterized.We compiled a database of NSCLC cases harboring NTRK fusions. We characterized the clinical, molecular, and histologic features of these cases with central review of histology.We identified 11 NSCLC cases harboring NTRK gene fusions verified by next-generation sequencing (NGS) and with available clinical and pathologic data, forming the study cohort. Fusions involved NTRK1 (7 cases) and NTRK3 (4 cases), with 5 and 2 distinct fusion partners, respectively. Cohort patients were 55% male, with a median age at diagnosis of 47.6 years (range 25.3-86.0) and a median pack year history of 0 (range 0-58). 73% of patients had metastatic disease at diagnosis. No concurrent alterations in KRAS, EGFR, ALK, ROS1, or other known oncogenic drivers were identified. Nine cases were adenocarcinoma, including 2 invasive mucinous adenocarcinomas and 1 adenocarcinoma with neuroendocrine features; one was squamous cell carcinoma; and one was neuroendocrine carcinoma. By collating data on 4872 consecutively screened NSCLC cases from unique patients, we estimate a frequency of NTRK fusions in NSCLC of 0.23% (95% CI 0.11-0.40).NTRK fusions occur in NSCLCs across genders, ages, smoking histories, and histologies. Given the potent clinical activity of TRK inhibitors, we advocate that all NSCLCs be screened for NTRK fusions using a multiplexed NGS-based fusion assay.

    View details for PubMedID 30215037

  • PDX models generated from a patient with metastatic colon adenocarcinoma display both spatial and temporal tumor heterogeneity Das, B., Karlovich, C., Camalier, C. E., Patidar, R., Chen, L., Datta, V., Walsh, W. D., McDermott, S. P., Vilimas, T., Fliss, P., McCutcheon, J. N., Peach, A., Ahalt-Gottholm, M., Bonomi, C., Dougherty, K., Carter, J., Kummar, S., Evrard, Y. A., Hollingshead, M. G., Williams, P. M., Doroshow, J. H. AMER ASSOC CANCER RESEARCH. 2018
  • Durability of responses to the combination of SD-101 and pembrolizumab in advanced metastatic melanoma: Results of a phase Ib, multicenter study Ribas, A., Medina, T., Kummar, S., Amin, A., Drabick, J. J., Barve, M., Daniels, G., Wong, D. L., Schmidt, E. V., Leung, A. C., Janssen, R. AMER ASSOC CANCER RESEARCH. 2018
  • First-in-human study of the epichaperome inhibitor PU-H71: clinical results and metabolic profile INVESTIGATIONAL NEW DRUGS Speranza, G., Anderson, L., Chen, A. P., Khanh Do, Eugeni, M., Weil, M., Rubinstein, L., Majerova, E., Collins, J., Horneffer, Y., Juwara, L., Zlott, J., Bishop, R., Conley, B. A., Streicher, H., Tomaszewski, J., Doroshow, J. H., Kummar, S. 2018; 36 (2): 230?39


    Background Molecular chaperone targeting has shown promise as a therapeutic approach in human cancers of various histologies and genetic backgrounds. The purine-scaffold inhibitor PU-H71 (NSC 750424), selective for Hsp90 in epichaperome networks, has demonstrated antitumor activity in multiple preclinical cancer models. The present study was a first in-human trial of PU-H71 aimed at establishing its safety and tolerability and characterizing its pharmacokinetic (PK) profile on a weekly administration schedule in human subjects with solid tumors refractory to standard treatments. Methods PU-H71 was administered intravenously over 1 h on days 1 and 8 of 21-day cycles in patients with refractory solid tumors. Dose escalation followed a modified accelerated design. Blood and urine were collected during cycles 1 and 2 for pharmacokinetics analysis. Results Seventeen patients were enrolled in this trial. Grade 2 and 3 adverse events were observed but no dose limiting toxicities occurred, thus the human maximum tolerated dose was not determined. The mean terminal half-life (T1/2) was 8.4 ± 3.6 h, with no dependency to dose level. A pathway for the metabolic disposal of PU-H71 in humans was derived from microsome studies. Fourteen patients were also evaluable for clinical response; 6 (35%) achieved a best response of stable disease for >2 cycles, with 2 patients remaining on study for 6 cycles. The study closed prematurely due to discontinuation of drug supply. Conclusions PU-H71 was well tolerated at the doses administered during this study (10 to 470 mg/m2/day), with no dose limiting toxicities.

    View details for PubMedID 28808818

  • The evolving paradigm of cancer trials NATURE REVIEWS DRUG DISCOVERY Kummar, S. 2018; 17 (4): 225?26

    View details for PubMedID 29269944

  • Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children NEW ENGLAND JOURNAL OF MEDICINE Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., Turpin, B., Dowlati, A., Brose, M. S., Mascarenhas, L., Federman, N., Berlin, J., El-Deiry, W. S., Baik, C., Deeken, J., Boni, V., Nagasubramanian, R., Taylor, M., Rudzinski, E. R., Meric-Bernstam, F., Sohal, D. S., Ma, P. C., Raez, L. E., Hechtman, J. F., Benayed, R., Ladanyi, M., Tuch, B. B., Ebata, K., Cruickshank, S., Ku, N. C., Cox, M. C., Hawkins, D. S., Hong, D. S., Hyman, D. M. 2018; 378 (8): 731?39


    Fusions involving one of three tropomyosin receptor kinases (TRK) occur in diverse cancers in children and adults. We evaluated the efficacy and safety of larotrectinib, a highly selective TRK inhibitor, in adults and children who had tumors with these fusions.We enrolled patients with consecutively and prospectively identified TRK fusion-positive cancers, detected by molecular profiling as routinely performed at each site, into one of three protocols: a phase 1 study involving adults, a phase 1-2 study involving children, or a phase 2 study involving adolescents and adults. The primary end point for the combined analysis was the overall response rate according to independent review. Secondary end points included duration of response, progression-free survival, and safety.A total of 55 patients, ranging in age from 4 months to 76 years, were enrolled and treated. Patients had 17 unique TRK fusion-positive tumor types. The overall response rate was 75% (95% confidence interval [CI], 61 to 85) according to independent review and 80% (95% CI, 67 to 90) according to investigator assessment. At 1 year, 71% of the responses were ongoing and 55% of the patients remained progression-free. The median duration of response and progression-free survival had not been reached. At a median follow-up of 9.4 months, 86% of the patients with a response (38 of 44 patients) were continuing treatment or had undergone surgery that was intended to be curative. Adverse events were predominantly of grade 1, and no adverse event of grade 3 or 4 that was considered by the investigators to be related to larotrectinib occurred in more than 5% of patients. No patient discontinued larotrectinib owing to drug-related adverse events.Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).

    View details for PubMedID 29466156

    View details for PubMedCentralID PMC5857389

  • Changing Landscape of Early Phase Clinical Trials: Beyond the Horizon NOVEL DESIGNS OF EARLY PHASE TRIALS FOR CANCER THERAPEUTICS Do, K., Takimoto, C. H., Kummar, S., Kummar, S., Takimoto, C. 2018: 1?6
  • Cold agglutinin disease burden: a longitudinal analysis of anemia, medications, transfusions, and health care utilization BLOOD ADVANCES Mullins, M., Jiang, X., Bylsma, L. C., Fryzek, J. P., Reichert, H., Chen, E. C., Kummar, S., Rosenthal, A. 2017; 1 (13): 839?48


    Cold agglutinin disease (CAD), a rare disease and subtype of autoimmune hemolytic anemia, is characterized by autoantibodies that bind to red blood cells at low temperatures. There is no established standard of care for CAD treatment and CAD cohort studies are limited by the rarity of the condition. The objectives of this study are to present the longitudinal experience of a CAD cohort from the United States, with a focus on anemia severity, use of medications and transfusions, and health care resource utilization. The Stanford Translational Research Integrated Database Environment database was used to retrospectively identify CAD patients diagnosed and treated at Stanford Health Care from 2000 to 2016. Twenty-nine patients were included in this analysis. There were 7.1 severe anemia events per patient-year observed over the follow-up time. For CAD patients treated at Stanford, there was a mean of 3.5 therapies per patient. Transfusions were given in at least 65% of the cohort with a mean of 11 transfusions per patient-year. For CAD-related health care use in the first year after disease onset, 93% used outpatient services with a median of 26 outpatient visits per patient. The data presented here likely represent the minimum number of events for these patients during this timeframe, as this single-center experience does not capture care from other providers. This longitudinal study of CAD patients demonstrates the severity of anemia and relapsing nature of the disease, even after administration of multiple therapies and transfusions.

    View details for PubMedID 29296728

    View details for PubMedCentralID PMC5727809

  • A phase 2 study of vorinostat in locally advanced, recurrent, or metastatic adenoid cystic carcinoma. Oncotarget Goncalves, P. H., Heilbrun, L. K., Barrett, M. T., Kummar, S., Hansen, A. R., Siu, L. L., Piekarz, R. L., Sukari, A. W., Chao, J., Pilat, M. J., Smith, D. W., Casetta, L., Boerner, S. A., Chen, A., Lenkiewicz, E., Malasi, S., LoRusso, P. M. 2017; 8 (20): 32918-32929


    Vorinostat is a histone deacetylase inhibitor (HDACi). Based on a confirmed partial response (PR) in an adenoid cystic carcinoma (ACC) patient treated with vorinostat in a prior phase 1 trial, we initiated this phase 2 trial.Vorinostat was administered orally 400 mg daily, 28 day cycles. The primary objective was to evaluate response rate (RR). Exploratory studies included whole exome sequencing (WES) of selected patients.Thirty patients were enrolled. Median age of patients was 53 years (range 21-73). Median number of cycles was 5 (range 1-66). Lymphopenia (n = 5), hypertension (n = 3), oral pain (n = 2), thromboembolic events (n = 2) and fatigue (n = 2) were the only grade 3 adverse events (AEs) that occurred in more than 1 patient. Eleven patients were dose reduced secondary to drug-related AEs. Two patients had a partial response (PR), with response durations of 53 and 7.2 months. One patient had a minor response with a decrease in ascites (for 19 cycles). Stable disease was the best response in 27 patients. Targeted and WES of 8 patients in this trial identified mutations in chromatin remodeling genes highlighting the role of the epigenome in ACC.Vorinostat demonstrated efficacy in patients with ACC supporting the inclusion of HDACi in future studies to treat ACC.

    View details for DOI 10.18632/oncotarget.16464

    View details for PubMedID 28415633

  • Clinical Activity of the gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis) JOURNAL OF CLINICAL ONCOLOGY Kummar, S., Coyne, G. O., Do, K. T., Turkbey, B., Meltzer, P. S., Polley, E., Choyke, P. L., Meehan, R., Vilimas, R., Horneffer, Y., Juwara, L., Lih, A., Choudhary, A., Mitchell, S. A., Helman, L. J., Doroshow, J. H., Chen, A. P. 2017; 35 (14): 1561-?
  • Evolution of early phase clinical trials in oncology. Journal of molecular medicine (Berlin, Germany) Bui, N. Q., Kummar, S. 2017


    The therapeutic armamentarium for the treatment of cancer has rapidly evolved with the advent of molecularly targeted and immuno-oncology agents. Dramatic and prolonged responses observed in patients with advanced cancers have created excitement and promise for expedited development of effective new treatments. However, this has also necessitated a rethinking of our early phase clinical trial designs and the process of optimally developing a novel agent. In this review, we discuss the current state and future directions of phase I clinical trials in oncology. Firstly, we cover the statistical methodologies behind rules and model-based dose escalation designs, and what the future holds for optimal dose selection beyond targeting the maximum tolerated dose. Next, we discuss the recent adoption of seamless expansion strategies to expedite drug development timelines, highlighted by the pembrolizumab KEYNOTE-001 trial, and potential pitfalls with this approach. Finally, we delve into the concepts behind genomic matching trials, including early success stories and the challenges that lie ahead.

    View details for PubMedID 29177698

  • Dosimetry and first human experience with 89Zr-panitumumab. American journal of nuclear medicine and molecular imaging Lindenberg, L., Adler, S., Turkbey, I. B., Mertan, F., Ton, A., Do, K., Kummar, S., Gonzalez, E. M., Bhattacharyya, S., Jacobs, P. M., Choyke, P. 2017; 7 (4): 195?203


    89Zr-panitumumab is a novel immuno-PET radiotracer. A fully humanized IgG2 antibody, panitumumab binds with high affinity to the extracellular ligand binding domain of EGFR. Immuno-PET with radiolabeled panitumumab is a non-invasive method that could characterize EGFR expression in tumors and metastatic lesions. It might also assist in selecting patients likely to benefit from targeted therapy as well as monitor response and drug biodistribution for dosing guidance. Our objective was to calculate the maximum dosing for effective imaging with minimal radiation exposure in a small subset. Three patients with metastatic colon cancer were injected with approximately 1 mCi (37 MBq) of 89Zr-panitumumab IV. Whole body static images were then obtained at 2-6 hours, 1-3 days and 5-7 days post injection. Whole organ contours were applied to the liver, kidneys, spleen, stomach, lungs, bone, gut, heart, bladder and psoas muscle. From these contours, time activity curves were derived and used to calculate mean resident times which were used as input into OLINDA 1.1 software for dosimetry estimates. The whole body effective dose was estimated between 0.264 mSv/MBq (0.97 rem/mCi) and 0.330 mSv/MBq (1.22 rem/mCi). The organ which had the highest dose was the liver which OLINDA estimated between 1.9 mGy/MBq (7.2 rad/mCi) and 2.5 mGy/MBq (9 rad/mCi). The effective dose is within range of extrapolated estimates from mice studies. 89Zr-panitumumab appears safe and dosimetry estimates are reasonable for clinical imaging.

    View details for PubMedID 28913158

  • Molecular insights into desmoid tumors. Oncotarget Bui, N., Kummar, S. 2017; 8 (53): 90608?9

    View details for DOI 10.18632/oncotarget.21293

    View details for PubMedID 29207578

    View details for PubMedCentralID PMC5710859

  • The root causes of pharmacodynamic assay failure SEMINARS IN ONCOLOGY Ferry-Galow, K. V., Makhlouf, H. R., Wilsker, D. F., Lawrence, S. M., Pfister, T. D., Marrero, A. M., Bigelow, K. M., Yutzy, W. H., Ji, J. J., Butcher, D. O., Gouker, B. A., Kummar, S., Chen, A. P., Kinders, R. J., Parchment, R. E., Doroshow, J. H. 2016; 43 (4): 484-491


    Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reagent and specimen quality are two major contributors to this problem. Minimizing all potential sources of variability in procedures for specimen collection, processing, and assay measurements is essential for meaningful comparison of pharmacodynamic biomarkers across sample time points. This is especially true in the evaluation of pre- and post-dose tumor biopsies, which suffer from high levels of tumor insufficiency due to variations in biopsy collection techniques and significant specimen heterogeneity within and across patients. Developing methods to assess heterogeneous biopsies is necessary in order to evaluate a majority of tumor biopsies collected for pharmacodynamic biomarker studies. Improved collection devices and standardization of methods are being sought in order to improve the tumor content and quality of tumor biopsies. In terms of reagent variability, we have found that stringent initial reagent qualification and quality control of R&D-grade reagents is critical to minimize lot-to-lot variability and prevent assay failures, especially for clinical pharmacodynamic questions, which often demand assay performance that meets or exceeds clinical diagnostic assay standards. Rigorous reagent specifications and use of appropriate assay quality control methodologies help to ensure consistency between assay runs, laboratories and trials to provide much needed pharmacodynamic insights into the activity of investigational agents.

    View details for DOI 10.1053/j.seminoncol.2016.06.006

    View details for Web of Science ID 000384870100007

    View details for PubMedID 27663480

  • Establishing proof of mechanism: Assessing target modulation in early-phase clinical trials SEMINARS IN ONCOLOGY Kummar, S., Khanh Do, K., Coyne, G. O., Chen, A., Ji, J., Rubinstein, L., Doroshow, J. H. 2016; 43 (4): 446-452


    Since modulation of the putative target and the observed anti-tumor effects form the basis for the clinical development of a molecularly targeted therapy, early-phase clinical trials should be designed to demonstrate proof-of-mechanism in tissues of interest. In addition to establishing safety and the maximum tolerated dose, first-in-human clinical trials should be designed to demonstrate target modulation, define the proposed mechanism of action, and evaluate pharmacokinetic-pharmacodynamic relationships of a new anti-cancer agent. Assessing target modulation in paired tumor biopsies in patients with solid tumors presents multiple challenges, including procedural issues such as patient safety, ethical considerations, and logistics of sample handling and processing. In addition, the availability of qualified biomarker assay technologies, resources to conduct such studies, and real-time analysis of samples to detect inter-species differences that may affect the determination of optimal sampling time points must be taken into account. This article provides a discussion of the challenges that confront the practical application of pharmacodynamic studies in early-phase clinical trials of anti-cancer agents.

    View details for DOI 10.1053/j.seminoncol.2016.06.002

    View details for Web of Science ID 000384870100003

    View details for PubMedID 27663476

  • Developing therapies for rare tumors: opportunities, challenges and progress EXPERT OPINION ON ORPHAN DRUGS Bradford, D., Reilly, K. M., Widemann, B. C., Sandler, A., Kummar, S. 2016; 4 (1): 93-103
  • Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy. Current opinion in oncology O'Sullivan Coyne, G., Chen, A., Kummar, S. 2015; 27 (6): 475-481


    The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents.The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies.Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.

    View details for DOI 10.1097/CCO.0000000000000238

    View details for PubMedID 26447876

  • Delivering on the promise: poly ADP ribose polymerase inhibition as targeted anticancer therapy CURRENT OPINION IN ONCOLOGY Coyne, G. O., Chen, A., Kummar, S. 2015; 27 (6): 475-481


    The article presents the rationale, clinical development, and current status of poly (ADP ribose) polymerase inhibitors (PARPis) as anticancer agents.The recent approval of olaparib in heavily pretreated patients with advanced ovarian cancer carrying a BRCA1/2 mutation represents a significant therapeutic advance for patients with this difficult to treat disease. Though olaparib is the first agent in this class to be approved, multiple PARPis are in various stages of clinical development, including in combination with other treatment modalities such as radiation, antiangiogenic agents, and cytotoxic chemotherapies.Clinical benefit has been observed with PARPis in patients with advanced BRCA1/2 mutant ovarian and breast cancers. Various PARPis, either as single agents or in combination, are being evaluated in the neoadjuvant, adjuvant, and metastatic settings.

    View details for DOI 10.1097/CCO.0000000000000238

    View details for Web of Science ID 000369624100007

    View details for PubMedCentralID PMC4636335

Footer Links:

Stanford Medicine Resources: